Research
Hormonal
Semaglutide did not offer significant advantages in lowering HbA1C levels compared to other hypoglycemic treatments.
Practitioners should be cautious in expecting significant HbA1C improvements with Semaglutide.
StrongRefutesmedium confidence
Although Semaglutide induced modest weight reductions, it did not offer significant advantages in lowering HbA1C levels compared to other hypoglycemic treatments.
Why this rating
Based on the study design involving a retrospective review of EMRs.
Source
Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia
Yazed AlRuthia et al. · Saudi Pharmaceutical Journal · 2024
DOI 10.1016/j.jsps.2024.102057
cohort · n=350Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →